lauric acid/hemorrhage

Lyen an sove nan clipboard la

Chwazi kalite sòt

3 rezilta yo

A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We investigated the antithrombotic activity of Z-335, a new thromboxane A2 receptor antagonist, using experimental thrombosis models, and also tested its effect on the rat tail bleeding time. Z-335 (0.1, 0.3, and 1 mg/kg, p.o.) dose-dependently prevented the occurrence of arachidonic acid-induced

Irritancy potential induced by surfactants derived from lysine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The ocular irritancy potential of surfactants of the anionic and non-ionic type, derived from lysine has been tested by the hen's egg test-choriollantoic membrane (HET-CAM) to correlate the potential irritation with the structure of the surfactant, in order to synthesize the less irritant surfactant

Hyperthermia-triggered UK release nanovectors for deep venous thrombosis therapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Deep vein thrombosis (DVT) is a common and lethal complication of surgery. In the clinic, thrombolytic drugs are primarily used for treating DVT. However, the utilization of thrombolytic drugs is limited due to the risk of urokinase (UK)-related hemorrhagic complications. In this paper, a binary

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye